⏳ Final hours! Save up to 60% OFF InvestingProCLAIM SALE

Medacta shares target raised by Morgan Stanley amid EPS growth

EditorEmilio Ghigini
Published 07/17/2024, 05:10 PM
XLS
-

On Wednesday, Morgan Stanley resumed coverage on Medacta International (MOVE:SW) shares, a Swiss medical device company, maintaining an Equal-weight rating on the stock. The firm also raised the price target to CHF 134.00 from CHF 130.00.

Medacta's shares are currently trading at 30 times price-to-earnings (P/E) and 15 times earnings before interest, taxes, depreciation, and amortization (EBITDA) based on Morgan Stanley's 2025 estimates.

These metrics are slightly below the five-year average of approximately 32 times P/E and 17 times EBITDA, and above the initial public offering (IPO) valuation of about 26 times P/E and 15 times EBITDA.

According to the firm's analysis, Medacta's stock is trading at a 1.5 times multiple relative to the European MSCI index, consistent with its five-year average. When compared to Swiss Medtech peers, including Alcon (NYSE:ALC), Straumann (STMN), Tecan (TECN), and Sonova (SOON), Medacta's shares are at a 12% premium based on P/E at 28 times but show a 15% discount on EBITDA at 18 times.

Morgan Stanley highlighted Medacta's earnings per share (EPS) growth as best-in-class for European MedTech, with growth in the high teens. However, the firm has below-consensus margin expansion forecasts and anticipates a possible recalibration following the first-half results and the Capital Markets Day. Consequently, the firm has decided to maintain an Equal-weight rating on the stock for the time being.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.